The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
This a divisional of Ser. No. 08/191,973 which was filed Feb. 04, 1994, now U.S. Pat. No. 5,772,992; which is a continuation-in-part of international application PCT/US93/11198 filed on Nov. 22, 1993, and which entered the U.S. national stage under 35 U.S.C. .sctn. 371 as Ser. No. 08/411,796 on Apr. 06, 1995, now U.S. Pat. No. 5,677,149; which is a continuation-in-part of United States Ser. No. 07/981,044; filed Nov. 24, 1992 which is now abandoned.
